SecBot SecBot
SECBOTREPLAY Home › Report › MRNA

MRNA · William Blair double-upgraded MRNA from Market Perform to Outperform on…

Moderna, Inc. · ANALYST-UPGRADE filed Aug 19, 2026 at 15:34 ET

At the news

MIXEDIMPACT 1/10

ANALYST-UPGRADE filed Aug 19, 2026 at 15:34 ET

William Blair double-upgraded MRNA from Market Perform to Outperform on August 19, 2026, a rare two-step move that signals a significant shift in the firm's view. The upgrade comes as MRNA trades at $174.38, far above the consensus mean price target of $50.84, implying a 243% downside to the average target. The consensus is heavily bearish with 18 Holds, 2 Sells, and 1 Strong Sell versus only 9 Buy/Strong Buy ratings. William Blair has a 51% accuracy rate on 273 calls with a 4.2% average return, placing it in the middle tier among covering firms. Despite the bullish upgrade, the stock faces headwinds from a 60.1% short interest ratio and CEO Stephane Bancel selling $28.7 million in shares on August 5. EPS revisions over the past 30 days show a mixed picture: 7 upward revisions for the current quarter but 7 downward, while next quarter saw 11 upward and 3 downward. The bottom line: this is a contrarian call from a mid-accuracy firm against a deeply bearish consensus, but the extreme price-to-target gap and insider selling temper conviction.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access